Cargando…

A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment

PURPOSE: The aim of this audit was to assess the overall experience and patient convenience of vaginal progesterone tablets (Lutigest(®), marketed as Endometrin(®) in the USA) used for luteal phase support (LPS) during in vitro fertilization (IVF) treatment. PATIENTS AND METHODS: This questionnaire-...

Descripción completa

Detalles Bibliográficos
Autores principales: Heine, Polly, Sellar, Laura, Whitten, Sue, Bajaj, Priti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726362/
https://www.ncbi.nlm.nih.gov/pubmed/29263708
http://dx.doi.org/10.2147/PROM.S140678
_version_ 1783285707664523264
author Heine, Polly
Sellar, Laura
Whitten, Sue
Bajaj, Priti
author_facet Heine, Polly
Sellar, Laura
Whitten, Sue
Bajaj, Priti
author_sort Heine, Polly
collection PubMed
description PURPOSE: The aim of this audit was to assess the overall experience and patient convenience of vaginal progesterone tablets (Lutigest(®), marketed as Endometrin(®) in the USA) used for luteal phase support (LPS) during in vitro fertilization (IVF) treatment. PATIENTS AND METHODS: This questionnaire-based audit included responses from 100 patients undergoing IVF treatment at six IVF clinics in the UK from September 2015 to November 2016. Fourteen days after starting progesterone supplementation for LPS during their IVF treatment, patients rated overall experience and perceived convenience of the prescribed progesterone by completing a questionnaire. RESULTS: Of the 100 patients included, 96 received vaginal progesterone tablets for LPS. Overall, 53.1% (51/96) indicated that the progesterone tablets were “very easy” to use; 42.7% (41/96) and 44.8% (43/96) found it “very convenient” or “neither convenient or inconvenient” to administer the tablet, respectively. Overall experience with using progesterone tablets was rated as “very comfortable” by 34.4% (33/96) and “neither comfortable or uncomfortable” by 56.3% (54/96) of patients. The applicator was used by 93.8% (90/96) of patients to administer the tablet, and 86.5% (83/96) indicated that the applicator was easy to clean for repeated use. A total of 33 patients had a previous IVF cycle during which they were prescribed vaginal progesterone pessaries for LPS. Compared with progesterone pessaries, the majority found treatment with progesterone tablets to be more comfortable (60.6%; 20/33) and more convenient (57.6%; 19/33) and indicated that the progesterone tablet was their preferred progesterone formulation for LPS (60.6%; 20/33). CONCLUSION: These findings offer insights into real-world patient experiences with the progesterone vaginal tablet formulation. The results suggest overall patient convenience, ease, and comfort with using progesterone vaginal tablets for LPS. The majority of patients found progesterone vaginal tablets more convenient and comfortable to use compared with progesterone pessaries.
format Online
Article
Text
id pubmed-5726362
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57263622017-12-20 A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment Heine, Polly Sellar, Laura Whitten, Sue Bajaj, Priti Patient Relat Outcome Meas Original Research PURPOSE: The aim of this audit was to assess the overall experience and patient convenience of vaginal progesterone tablets (Lutigest(®), marketed as Endometrin(®) in the USA) used for luteal phase support (LPS) during in vitro fertilization (IVF) treatment. PATIENTS AND METHODS: This questionnaire-based audit included responses from 100 patients undergoing IVF treatment at six IVF clinics in the UK from September 2015 to November 2016. Fourteen days after starting progesterone supplementation for LPS during their IVF treatment, patients rated overall experience and perceived convenience of the prescribed progesterone by completing a questionnaire. RESULTS: Of the 100 patients included, 96 received vaginal progesterone tablets for LPS. Overall, 53.1% (51/96) indicated that the progesterone tablets were “very easy” to use; 42.7% (41/96) and 44.8% (43/96) found it “very convenient” or “neither convenient or inconvenient” to administer the tablet, respectively. Overall experience with using progesterone tablets was rated as “very comfortable” by 34.4% (33/96) and “neither comfortable or uncomfortable” by 56.3% (54/96) of patients. The applicator was used by 93.8% (90/96) of patients to administer the tablet, and 86.5% (83/96) indicated that the applicator was easy to clean for repeated use. A total of 33 patients had a previous IVF cycle during which they were prescribed vaginal progesterone pessaries for LPS. Compared with progesterone pessaries, the majority found treatment with progesterone tablets to be more comfortable (60.6%; 20/33) and more convenient (57.6%; 19/33) and indicated that the progesterone tablet was their preferred progesterone formulation for LPS (60.6%; 20/33). CONCLUSION: These findings offer insights into real-world patient experiences with the progesterone vaginal tablet formulation. The results suggest overall patient convenience, ease, and comfort with using progesterone vaginal tablets for LPS. The majority of patients found progesterone vaginal tablets more convenient and comfortable to use compared with progesterone pessaries. Dove Medical Press 2017-12-08 /pmc/articles/PMC5726362/ /pubmed/29263708 http://dx.doi.org/10.2147/PROM.S140678 Text en © 2017 Heine et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Heine, Polly
Sellar, Laura
Whitten, Sue
Bajaj, Priti
A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment
title A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment
title_full A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment
title_fullStr A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment
title_full_unstemmed A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment
title_short A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment
title_sort questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (lutigest(®)) for luteal phase support during ivf treatment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726362/
https://www.ncbi.nlm.nih.gov/pubmed/29263708
http://dx.doi.org/10.2147/PROM.S140678
work_keys_str_mv AT heinepolly aquestionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment
AT sellarlaura aquestionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment
AT whittensue aquestionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment
AT bajajpriti aquestionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment
AT heinepolly questionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment
AT sellarlaura questionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment
AT whittensue questionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment
AT bajajpriti questionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment